Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biogen
The primary objective of this study is to determine the impact of early versus delayed initiation of treatment on the long-term physical status of patients with relapsing forms of MS measured by the self-reported EDSS.
Primary endpoints for this study were as follows:
1. Changes in EDSS score from baseline for original Avonex® pivotal trial
2. Percentage of patients with EDSS scores less than or equal to 4
3. Percentage of patients with EDSS scores less than or equal to 6
4. Percentage of patients with EDSS scores less than or equal to 7
Secondary endpoints were:
1. Percentage of patients alive
2. Percentage of patients living independently
3. SF 36 Quality of Life status
4. Self-reported VAS of independence with self-care
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
1. Patients having completed at least 2 years of treatment (Avonex® or placebo) in the original Avonex® pivotal trial.
2. Subjects (or their caregivers) must be willing to complete a multi-page questionnaire.
3. Signed written informed consent form
You may not be if
1. Unwillingness or inability to comply with the requirements of this protocol.
2. Any other reasons that, in the opinion of the Investigator, the subject is determined to be unsuitable for enrollment into this study
